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Cross-Linking of SPINK6 by Transglutaminases
Protects from Epidermal Proteases
Jan Fischer1, Yulia Koblyakova1, Ties Latendorf1, Zhihong Wu1 and Ulf Meyer-Hoffert1
Extracellular kallikrein-related peptidases (KLKs) are involved in the desquamation process and the initiation of
epidermal inflammation by different mechanisms. Their action is tightly controlled by specific protease inhibitors.
Recently, we have identified the serine protease inhibitor of Kazal-type (SPINK) 6 as a selective inhibitor of KLKs in
human stratum corneum extracts. As SPINK6 is expressed in the same localization as transglutaminases (TGM)
and contains TGM substrate motifs, SPINK6 was tested to be cross-linked in the epidermis. Recombinant SPINK6
was shown to be cross-linked to fibronectin (FN) by TGM1 by western blot analyses. Moreover, SPINK6 was cross-
linked in epidermal extracts and cultured keratinocytes by immunoblotting analyses. The use of TGM1 and TGM3
resulted in different immunoreactivities in western blot analyses of SPINK6 and epidermal extracts, suggesting
substrate specifities of different TGMs for SPINK6 cross-linking in the epidermis. Conjugated SPINK6 exhibited
protease inhibitory activity in keratinocytes and stratum corneum extracts; cross-linked SPINK6 protected FN from
KLK5-mediated cleavage, whereas a lower KLK-inhibiting SPINK6-GM mutation did not. In conclusion, we
demonstrated that SPINK6 is cross-linked in keratinocytes and human epidermis and remains inhibitory active.
Thus, cross-linked SPINK6 might protect specific substrates such as FN from KLK cleavage and contributes to the
regulation of proteases in the epidermis.
Journal of Investigative Dermatology (2013) 133, 1170–1177; doi:10.1038/jid.2012.482; published online 10 January 2013
INTRODUCTION
Epidermal proteases have an important role in epidermal
barrier function (Meyer-Hoffert, 2009). Kallikrein-related
peptidases (KLKs) belong to a group of 15 serine proteases
with trypsin-like or chymotrypsin-like activity, whose genes
are clustered at chromosome 19q13.4 (Yousef and Diamandis,
2001). In the skin, multiple KLKs are expressed and secreted
by lamellar bodies in the extracellular space of the stratum
granulosum (Ishida-Yamamoto et al., 2005; Komatsu et al.,
2005; Shaw and Diamandis, 2007). In the stratum corneum,
some KLKs are responsible for the degradation of intercellular
adhesions molecules such as desmoglein and thus for the
desquamation process (Ekholm et al., 2000; Caubet et al.,
2004; Borgono et al., 2007). In addition, KLKs are capable of
degrading adhesion molecules of the extracellular matrix, and
therefore aberrant KLK expression has been implicated in
tumor invasion and metastasis (Klucky et al., 2007; Bayani and
Diamandis, 2011; Lose et al., 2011).
In skin diseases such as rosacea, psoriasis, and atopic
dermatitis, elevated KLK levels have been observed. They
contribute to the inflammation reactions by several mechan-
isms including processing of biologically inactive cathelicidin
to inflammatory active fragments by KLK5 (Yamasaki et al.,
2007). Moreover, KLK7 and KLK13 are capable of cleaving
pro-IL-1b (Nylander-Lundqvist and Egelrud, 1997; Yao et al.,
2006). KLKs can activate the proteinase-activating receptor-2,
resulting in the production of the proallergic thymic stromal
lymphopoetin (Briot et al., 2009). TSLP causes, synergistically
with IL1b and TNFa, a Th2-mediated immune response,
which has an essential role in atopic dermatitis. The activity
of KLKs is controlled by proteinase inhibitors preferentially of
the serine protease inhibitor of Kazal-type (SPINK) family.
Mutations in the SPINK5 gene result in Netherton’s disease
(Chavanas et al., 2000), an inherited inflammatory skin
disease with enhanced epidermal KLKs activity, severe
congenital erythroderma, bamboo hair defects, and atopic
diathesis.
Our work group has purified previously unreported mem-
bers of the SPINK family, namely SPINK9 and SPINK6, from
stratum corneum extracts. SPINK6 and SPINK9 contain both a
single Kazal-type domain. SPINK9 is expressed at palmoplan-
tar sites and its inhibition is restricted to KLK5, whereas
SPINK6 is expressed at the entire body and efficiently inhibits
several KLKs (Brattsand et al., 2009; Meyer-Hoffert et al.,
2009, 2010; Kantyka et al., 2011; Lu et al., 2012). SPINK6
inhibits desquamation in an ex vivo model and might
contribute to the epidermal barrier function of the stratum
corneum. The stratum corneum consists mainly of insoluble
proteins and lipids. Epidermal transglutaminases (TGM)
contribute to the formation of this protective shield by
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cross-linking between glutamine and lysine residues of different
polypeptides and sphingolipids (Nemes and Steinert, 1999).
TGMs and SPINK6 are expressed in the same localizations in
the epidermis. SPINK6 contains Lys and Glu residues, which
could act as substrates for TGM that may enable SPINK6 to be
cross-linked to extracellular matrix proteins, thus anchoring the
inhibitor at its site of action. Therefore, we investigated whether
SPINK6 is a substrate of TGMs in the epidermis and whether
this affects the regulation of KLKs.
RESULTS
SPINK6 is a substrate for TGM-mediated cross-linking
Fluorescence staining of SPINK6 and TGM1 and TGM3
revealed colocalization of these proteins in the stratum
granulosum and stratum corneum (Figure 1), which suggests
possible interaction of SPINK6 with these epidermal TGM.
Taken that fibronectin (FN) is a well-known substrate for
TGMs, SPINK6 was incubated together with FN and TGM1.
Western blot analyses showed that SPINK6 is cross-linked to FN
in vitro (Figure 2a). AtB95 kDa, the intermediate product of the
recombinant TGM1 (90 kDa) and SPINK6 (6 kDa) was detected.
To test whether cross-linking of SPINK6 occurs with natural
epidermal TGM partners, epidermal extracts were incubated
with or without SPINK6 and TGM1 and TGM3, which
resulted both in multiple higher bands (Figure 2b). The
staining pattern was different, depending on the transgluta-
minase used. For TGM1, a strong signal between 52 and
72 kDa was observed, whereas a high-molecular-weight
signal (4250 kDa) was seen after treating the epidermis
extract with SPINK6 together with TGM3, suggesting that
these TGM exhibit diverse substrate specifities.
Western blot analyses of differentiated normal human
epidermal keratinocyte (NHEK) extracts showed distinct
higher molecular bands (Figure 2c). The addition of recombi-
nant SPINK6 resulted in an enhancement of these bands,
which was diminished by the TGM inhibitor Z-DON. Z-DON
is a small peptide-based transglutaminase inhibitor with a
DON (6-diazo-5-oxo-norleucine) core, which is similar to
glutamine and is alkylated to the active center cysteine of
TGM in an irreversible manner. Interestingly, the addition of
Z-DON alone to NHEK cells resulted in weaker SPINK6
immunoreactive bands. The addition of biotinylated SPINK6
to cultured NHEKs resulted in additional bands and a higher
background, supporting the fact (Figure 2d) that SPINK6 is
covalently bound to NHEKs.
Next, cryosections of healthy human skin were incubated
with SPINK6 together with or without Z-DON, followed by
rigorous washing to release unbound material. Subsequent
fluorescent staining using affinity-purified SPINK6 antibodies
resulted in an increase of SPINK6 immunoreactivity in the
epidermis after SPINK6 was added (Figure 3). The presence of
Z-DON partially inhibited this effect.
Cross-linked SPINK6 exhibits proteolytic inhibitory activity and
protects FN from KLK-mediated cleavage
To clarify whether conjugated SPINK6 still acts as a protease
inhibitor, FN was immobilized onto high-adsorption ELISA
plates, and after washing 50 nM SPINK6 was conjugated by
TGM1. Unbound SPINK6 was removed by washing, and
subsequently 0.8 nM KLK14 and the KLK14-substrate GPR-
AMC were added. KLK14 activity was significantly reduced
when SPINK6 was bound to FN (Figure 4a).
Next, we questioned whether SPINK6 cross-linked to NHEK
exhibits protease inhibitory activity. After 24 hours of incuba-
tion of NHEKs with 0.6mM SPINK6 and subsequent washing of
the trypsin substrate, GPR-AMC was added and trypsin-like
activity was monitored for 6 hours (Figure 4b). In differentiated
keratinocytes, the addition of SPINK6 resulted in a signifi-
cantly reduced trypsin-like activity of NHEKs. In contrast, in
undifferentiated NHEKs, when TGM are known to be not
expressed (Steinert et al., 1996), no reduction of trypsin-like
activity after treatment with SPINK6 was observed, even when
KLK14 was added in order to exclude that no proteases
inhibited by SPINK6 were present.
Figure 1. Serine protease inhibitor of Kazal-type 6 (SPINK6) colocalizes to epidermal transglutaminases (TGM). Paraffin-embedded skin sections were stained
with fluorescent antibodies against SPINK6 (green, a, e); TGM1 (red, b); TGM3 (red, f); and Hoechst 33258 (blue c, g). Merged image of (a–c) is shown in (d) and
merged image of (e–g,) is shown in (h). Colocalization of SPINK6 and TGMs result in yellow. Bar¼100mm.
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To further test whether cross-linking of SPINK6 occurs
under physiological conditions, human callus extracts were
incubated with SPINK6 in the absence or presence of TGM1
(Figure 4c). Western blot analyses revealed that soluble
SPINK6 (6 kDa) totally disappeared, even when TGM1 was
not added, and a strong signal higher than 260 kDa appeared.
This effect was dependent on the Ca2þ concentration and was
reversed by the addition of EDTA (Supplementary Figure S1
online), indicating that SPINK6 was cross-linked by active
calcium-dependent TGM. The addition of TGM1 to callus
extract and SPINK6 resulted in no detectable free SPINK6 and
no enhancement of higher bands. This might be caused by
conjugation of SPINK6 to very large proteins, which did not
enter the SDS–PAGE. The samples were diluted in assay
buffer. KLK14 (1 nM) and subsequently 0.025 mM GPR-AMC
were added to measure the proteolytic activity (Figure 4d). The
callus extract inhibited KLK14 activity by 15% under the given
condition, indicating that the inhibition of KLK14 by callus
inhibitors is greater than the remaining trypsin-like protease
activity. The addition of 10 nM SPINK6 resulted in a significant
decrease of trypsin-like activity. The presence of TGM1 had
no further influence on these effects. The results suggest that
SPINK6 was linked to callus proteins and remained at least
partially active as a protease inhibitor. Thus, the disappear-
ance of free SPINK6 in the immunoblot does not result from
unspecific proteolytic degradation and might come from high-
molecular-weight binding partners not entering the SDS–
PAGE.
After FN was bound to SPINK6 and unbound SPINK6 was
subsequently removed by ultrafiltration, KLK5 was added
(Figure 5). FN was cleaved by KLK5 in a time-dependent
manner. An anti-FN western blot resulted in a weaker signal at
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Figure 2. Serine protease inhibitor of Kazal-type 6 (SPINK6) is a substrate for transglutaminase (TGM)-mediated cross-linking. (a) a-SPINK6 western blot of
different incubations of SPINK6, TGM1, and fibronectin (FN) in cross-linking buffer in vitro for 3 hours at 37 1C. (b) Human epidermis extracts were incubated in
the absence or presence of 150 ng SPINK6 in cross-linking buffer either with TGM1 or TGM3 and applied to an a-SPINK6 western blot. (c) Differentiated normal
human epidermal keratinocytes (NHEKs) were preincubated with or without the cross-linking inhibitor Z-DON for 20 minutes before adding SPINK6 for 8 hours.
After washing, cells were lysed for 20 minutes in lysis buffer. Relative protein concentrations determined with nanodrop were normalized with lysis buffer, and
20ml was applied to the western blot. For the control, 135 ng of SPINK6 was used. (d) Biotinylated SPINK6 was incubated with differentiated NHEKs and TGM1 as
in described in (c) and applied to a western blot. A streptavidin–peroxidase conjugate was used to stain the biotinylated SPINK6.
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260 kDa and two main fragments at B70 and 40 kDa. No
fragments appeared when SPINK6 was cross-linked to FN,
indicating that cross-linked SPINK6 effectively protects FN
from KLK5 cleavage. In order to test whether the protection of
FN is due to the proteolytic inhibitory activity and not due to
steric protection from cleavage sites, a low KLK-inhibiting
SPINK6 mutation, SPINK6-GM (Ki¼82 nM), was created and
cross-linked to FN in the same manner. SPINK6-GM did not
protect FN from KLK5-mediated cleavage after cross-linking.
DISCUSSION
In this study, we demonstrate that SPINK6 is a substrate for
epidermal TGM. Protein–protein cross-linking by TGMs is an
important event in the formation of the stratum corneum but
also occurs in many other regions of the body. During the first
reaction step of the TGM-mediated cross-linking, the
g-carboxamide group of a glutamine residue forms a thiol
ester with an active site cysteine of the TGM. In the second
deacylation step of the transglutamination reaction, the acti-
vated thioester usually undergoes an acyl transfer to an
e-amino group of a second substrate lysine residue. By using
only SPINK6 together with TGM1, we only observed a single
immunoreactive product, which fits to the size of SPINK6
together with TGM1 (96 kDa) but no other multimere products
of SPINK6. This suggests that there is only one cross-linking
reaction between SPINK6 and TGM1. After incubating
SPINK6 and epidermal extracts with TGM1 or TGM3, the
resulting different band patterns indicate that SPINK6 is
conjugated to diverse substrates with different preferences
for both TGM. In contrast to the in vitro cross-linking with FN,
nearly all SPINK6 was bound in the presence of epidermal
extracts under comparable conditions, indicating a better
specificity toward other epidermal substrates. Different sub-
strate specificities for TGM1 and TGM3 were mentioned in
the literature (Candi et al., 1999), although no distinct
consensus sequences for different TGM were identified so
far. The nature of the glutamine and the neighboring residues
are important for the cross-linking reaction, as a positively
charged residue next to the glutamine residue dampens the
cross-linking reaction (Coussons et al., 1992), whereas other
studies have shown the importance of charged amino acids
around the glutamine residue (Aeschlimann et al., 1992;
Sugimura et al., 2008; Yamane et al., 2010). In SPINK6,
three out of four glutamines (Q4, Q11, and Q30) follow a
QxxF motif (where x is any amino acid and F a hydrophobic
acid). This motif was also observed for the cross-linked
protease inhibitors trappin-2 and secretory leukocyte
protease inhibitor (Guyot et al., 2005; Baranger et al., 2011).
Our data support the hypothesis that a hydrophobic residue
þ 3 to glutamine is a common motif for TGMs.
Taking cryosections, we demonstrated that recombinant
SPINK6 is bound to the epidermis ex vivo. Fluorescent
microscopy revealed that the expression of SPINK6 depended
on the differentiation status of the keratinocytes with a
maximum in the stratum granulosum. TGM1 and TGM3 were
shown to be expressed intracellularly (Iizuka et al., 2003), and
here they colocalized with SPINK6, suggesting that cross-
linking starts in the living keratinocytes. Colocalization was
also observed in the stratum granulosum and stratum
corneum, indicating that cross-linking of SPINK6 might
Figure 3. Serine protease inhibitor of Kazal-type 6 (SPINK6) is cross-linked to epidermal substrates ex vivo. Immunofluorescent staining of cryosections using
anti-SPINK6 antibodies is shown. Skin cryosections were incubated with buffer control (a), with the transglutaminase inhibitor Z-DON (b), with recombinant
SPINK6 (c), and recombinant SPINK6 together with Z-DON (d) overnight. After rigorous washing (three times for 5 minutes in buffer solution), sections were
stained against SPINK6. Bar¼ 100mm.
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occur in different epidermal areas. This might be modulated
by the TGM activation, e.g., by calcium availability and
others. An increased fluorescent signal especially in the
suprabasal layers was detected in cryosections of human
skin after incubation with recombinant SPINK6. This signal
was partially blocked by adding of the small peptide-based
transglutaminase inhibitor Z-DON (Figure 3), which is able to
enter cells and shows inhibition of different TGMs with
different efficiency (McConoughey et al., 2010; Schaertl
et al., 2010). Western blot analysis from differentiating
cultured keratinocytes showed immunoreactive bands at
higher-molecular-weight levels. The intensity of the bands
increased after the addition of SPINK6 to cultured
keratinocytes and was reduced by the addition of Z-DON,
suggesting that SPINK6 was cross-linked to specific
keratinocyte substrates, which was further supported by
cross-linking biotinylated SPINK6 to NHEK cells. As SPINK6
was purified from stratum corneum extracts in its
unconjugated form (Meyer-Hoffert et al., 2010), this cross-
linking is not complete in vivo. So far, other SPINK members
were not shown to be cross-linked by TGMs. The same or
similar extraction methods of stratum corneum extracts did not
reveal higher-molecular-weight immunobands for SPINK9
(Meyer-Hoffert et al., 2009) and lympho-epithelial Kazal
type–related inhibitor (Fortugno et al., 2011), suggesting
100
85
70
55
25
0
FN
+S
PIN
K6
FN
+S
PIN
K6
+T
GM
1
FN
+T
GM
1 FN
NH
EK
NH
EK
 + 
SP
INK
6
NH
EK
NH
EK
 + 
SP
INK
6
***
Differentiated
KL
K1
4 
ac
tiv
ity
 (%
)
100
85
70
55
25
0
100
***
85
70
55
25
0
Undifferentiated
G
PR
 a
ct
ivi
ty
 (%
)
(kDa)
260
135
42
10
Callus
SPINK6
TGM1
+ + + +
+ + + +
+ + +
100
85
70
55
25
0
G
PR
 a
ct
ivi
ty
 (%
)
KLK14
Callus
SPINK6
TGM1
+ + + + +
+ + + +
+ +
+ +
*** ** **
Figure 4. Cross-linked serine protease inhibitor of Kazal-type 6 (SPINK6) inhibits trypsin-like proteases. (a) Fibronectin (FN) was coated on a 96-well plate and
incubated with 100 nM SPINK6 or SPINK6 with transglutaminase (TGM)1 (n¼ 6). Kallikrein-related peptidase 14 (KLK14) next to GPR-AMC was added and activity
was measured. As controls, only FN or FN with TGM1 was used. (b) Normal human epidermal keratinocytes (NHEKs) were differentiated by the addition of 1 mM
Ca2þ to the medium or not. After a 24-hour treatment with or without 0.6mM SPINK6 (n¼ 6), cells were washed thoroughly and trypsin-like activity was measured
after the addition of 2 nM KLK14 (undifferentiated cells only) and 0.05 mM GPR-AMC. (c, d) Human callus extracts were incubated with or without SPINK6 in the
absence or presence of TGM1 for 4 hours at 37 1C. One part of the sample was applied to a a-SPINK6 western blot (c), and the other part was given to 1 nM KLK14
and 0.025 mM GPR-AMC activity for activity measurement. The experiment was repeated twice with different callus extracts in triplicates. The mean activities were
plotted with SD (a, b, d).
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Figure 5. Protein–protein cross-linking with serine protease inhibitor of Kazal
type 6 (SPINK6) protects fibronectin (FN) from kallikrein-related peptidase
5 (KLK5) cleavage. Anti-fibronectin western blot is shown. After FN was
cross-linked to SPINK6 and the low KLK5-inhibiting SPINK6-GM, unbound
SPINK6 was subsequently removed by ultrafiltration. KLK5 was added and
incubated for the indicated time points. A representative experiment out of
three independent ones is shown.
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dissimilar functions of SPINK6 compared with SPINK9 and
lympho-epithelial Kazal type–related inhibitor in human skin
and might explain the ostensible redundancy of KLK inhibitors
in human epidermis.
The cross-linking of SPINK6 might be important for the
protection of distinct proteins from KLK5-mediated cleavage.
Functional analysis of cross-linked SPINK6 to FN revealed
inhibitory activity toward KLK14 and protection from KLK5-
mediated cleavage. Even when SPINK6 is cross-linked to
various interaction partners in callus extracts and cultured
keratinocytes, it still exhibits inhibitory activity (Figure 4). To
our knowledge, this is a previously unreported description that
a protein is protected from proteolytic cleavage by TGM-
mediated cross-linking. Cross-linked secretory leukocyte pro-
tease inhibitor and trappin-2 inhibit proteases such as elastase
and proteinase 3 as well (Guyot et al., 2005; Baranger et al.,
2011). Moreover, cystatin alpha is covalently bound to the
stratum corneum by transglutaminase (Takahashi et al., 1994),
suggesting that cross-linkage of protease inhibitors might be a
general mechanism in human skin to control proteolytic
enzymes. The uppermost skin is frequently in contact with
water, and hence covalently bound SPINK6 would not be
washed away. Moreover, bound SPINK6 protects specific
target proteins from proteolytic cleavage. This might be
particularly important in the stratum corneum, where active
proteases such as KLKs are present and proteins cannot be
renewed by transcription.
In conclusion, we demonstrated that SPINK6 is cross-linked
in human epidermis and that conjugated SPINK6 is still
inhibitory active. Bound SPINK6 protects its conjugation
partners such as FN from KLK-mediated cleavage, which
might be relevant for epidermal barrier function.
MATERIALS AND METHODS
SPINK6 was recombinantly expressed in Escherichia coli, and
polyclonal goat anti-SPINK6 antibodies were produced and purified
as previously described (Meyer-Hoffert et al., 2010). For SPINK6-GM
mutation, the existing pSUMO3-SPINK6 was used as a template for
the following PCR reactions using TaqE polymerase (genaxxon
bioscience GmbH, Ulm, Germany): One forward primer with the
mutations R42G and E43M (ctg cac tgg aa tgt cta acc cac act gtg g) was
used with the existing reversed primer, and in a second reaction one
reversed primer with the mutations R42G and E43M (gtt aga cat tcc agt
gca gta gac ctt ggt g) was used with the existing forward primer. After
gel purification, another PCR reaction was performed using both
products as templates and existing SPINK6-pSUMO3 forward and
reverse primers. The gel-purified product was inserted in the
pSUMO3 vector as previously described (Meyer-Hoffert et al.,
2010). The correct sequence was confirmed by sequencing and the
expected protein mass after expression was confirmed by mass
spectrometry. SPINK6-GM exhibited a Ki of 82 nM against KLK5. To
biotinylate SPINK6, 1.6 mmol D-biotin-N-hydroxysuccinimidester
(biotin-NHS, Roche, Basel, Switzerland) was incubated with
0.17 mmol SPINK6 in 40ml of phosphate buffer, pH 7.0, for 6 hours
at room temperature. After purifying biotinylated SPINK6 by reversed
phase chromatography, the sample was lyophilized and stored at
 20 1C before use. All proteolytic activity assays were performed in
a Twinkle LB 970 reader (Berthold Technologies; Bad Wildbad,
Germany) at 355/460 nm ex/em wavelength. TGM1 and TGM3 were
purchased from Zedira (Darmstadt, Germany). Skin samples were
taken from healthy volunteers. The study was approved by the
authors’ Institutional Review Board University Kiel, Germany. The
Declaration of Helsinki protocols was followed and patients gave
their written and informed consent.
Cross-linking assays
Equimolar amounts (0.45mM) of native SPINK6 and FN were incu-
bated in cross-linking buffer (20 mM Tris pH 7.6, 50 mM NaCl, 10 mM
Ca2þ , 1 mM EDTA) in the presence or absence of 2 U transglutami-
nase (TGM)1 at 37 1C for 4 hours in a total volume of 25ml and
subsequently stopped using 20 mM EDTA. Samples were reduced with
5 mM DTT in the sample buffer before performing SDS–PAGE/western
blot.
For KLK5 degradation of SPINK6-bound FN, 413mM FN together
with or without 825mM SPINK6 or SPINK6-GM was incubated in
cross-linking buffer with 20 U TGM1 at 30 1C overnight. To remove
unbound SPINK6/SPINK6-GM, samples were applied to a vivaspin
ultrafiltration tube (30,000 Da, Sartorius AG, Goettingen, Germany)
and centrifuged at 14,000 g for 4 minutes three times by adding 300ml
of 0.1 M Tris, pH 8, 5 mM EDTA, 0.15 M NaCl, and 0.05% Tween to
each tube between each step. Each sample was adjusted to 300ml
and 100 ng KLK5 (R&D Systems, Wiesbaden, Germany) was applied
at 37 1C. Samples were collected at different time points and stored at
 20 1C. The SDS–PAGE was run under reducing conditions, and for
the western blot a polyclonal rabbit anti-FN antibody (Sigma-Aldrich
Biochemie, Hamburg; Germany) was used. Western blots were
detected using Lumi-LightPLUS (Roche Diagnostics Deutschland
GmbH, Mannheim, Germany).
The epidermis from human skin was scratched from the dermis
after 4 hours of incubation in Tris-EDTA buffer. After dissolving the
material in 7 M urea and 2 M thiourea, it was homogenized in a
SpeedMill PLUS Homogenisator (Analytik Jena AG, Jena, Germany)
four times for 30 seconds, centrifuged at 14,000 g, and the super-
natant was stored at  20 1C. Four microliter of epidermis extract was
incubated in cross-linking buffer with or without SPINK6 in the
absence or presence of either TGM1 or TGM3 at 37 1C for 4 hours. A
concentration of 1 mM DTT in the sample buffer was added before
loading to SDS–PAGE. SDS–PAGE and western blot analyses were
performed with equal volumes of samples under reducing conditions
in the sample buffer.
NHEKs were isolated from human foreskin and cultivated in
collagen-coated 12-well plates (NUNC, Roskilde, Denmark). After
reaching 100% confluence, 1 mM Ca2þ was added to the used EpiLife
medium (Invitrogen, Darmstadt, Germany) for 6 days. 100mM Z-DON
diluted in DMSO was preincubated 20 minutes before 4mg ml 1
SPINK6 was added with the same DMSO concentration. For the
control experiments, only DMSO was used. For a second experiment,
4mg ml 1 SPINK6 or biotinylated SPINK6 was given with or without
3 U TGM1 to differentiated NHEK cells. After incubation for 6 hours,
the cells were washed three times with PBS buffer. Subsequently, they
were incubated in 150ml of lysis buffer (50 mM HEPES, pH 7.4, 1%
TritonX100, 0.1% SDS, 150 mM NaCl, 10 mM EDTA, Roche complete
protease inhibitor) for 20 minutes at room temperature. After freezing,
the cells were centrifuged for 5 minutes at 14,000 g, and relative
concentrations of the supernatant were adjusted with lysis buffer after
nanodrop measuring. Western blot analyses using actin antibodies
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were performed as internal controls (data not shown). In the second
experiment, a streptavidin–peroxidase conjugate (Roche) was used at
1:10,000 to stain biotinylated SPINK6.
Cryosections of healthy skin were incubated with 18mg ml 1
recombinant SPINK6 with or without 200mM Z-DON in cross-linking
buffer. After washing for 5 minutes three times, sections were fixated
with 4% formaldehyde for 30 minutes. SPINK6 was stained using
polyclonal goat anti-SPINK6 antibodies followed by chicken anti-goat
Alexa Fluor 488 antibodies (Invitrogen), and sections were visualized
using an Olympus IX50 fluorescent microscope and the software
‘‘analySIS getIT’’ (Olympus, Hamburg, Germany).
Protease activity assays
A volume of 50ml of binding buffer (20 mM Tris, pH 7.4, 50 mM NaCl)
containing 200 nM FN (Sigma-Aldrich) was coated onto a 96-well
plate (NUNC Maxisorp) at 37 1C for 1 hour. After washing twice, 50ml
of cross-linking buffer (20 mM Tris pH 7.6, 50 mM NaCl, 10 mM Ca2þ )
was added with or without 100 nM SPINK6 and with or without 2 U
TGM1 at 37 1C for 2 hours. After washing three times, a total volume
of 100ml of assay buffer (20 mM Tris pH 7.6, 50 mM NaCl, 5 mM
EDTA) together with 0.8 nM human KLK14 (R&D Systems) and
subsequently 0.05 mM GPR-AMC (Bachem Distribution Services
GmbH, Weil am Rhein, Germany) were added. Cleavage of GPR-
AMC was monitored for 7 hours. Initial velocities were determined
with linear regression and plotted with SD (n¼ 6).
NHEKs were cultivated in 24-well plates (NUNC) and grown in
EpiLife medium (Invitrogen). To induce differentiation, 1 mM Ca2þ
was added to the culture medium for 6 days. Cells were treated with
or without 4mg ml 1 SPINK6 for 16 hours (n¼ 6) in cross-linking
buffer. The supernatant was collected and cells were washed three
times with PBS buffer before 0.05 mM GPR-AMC was added. Activity
was measured for 6 hours at 25 different positions in each well. The
mean was taken as one data point for an activity curve for each well.
Initial velocities were determined by linear regression and plotted
with their SD.
Total proteins from plantar callus were extracted as described
(Meyer-Hoffert et al., 2009). Callus extract (final concentration
0.36mgml 1) was incubated with or without 5 ngml 1 SPINK6 in
cross-linking buffer and/or 2 U TGM1 at 37 1C for 4 hours. For western
blot analyses, 9mg of callus extract was loaded to each lane, with a
total of 135 ng of SPINK6 in each lane. For activity assay,
0.0137mgml 1 callus extract with or without 10 nM SPINK6 was
diluted in assay buffer (0.1 M Tris pH 7.6, 5 mM EDTA, 150 mM NaCl,
0.05% Tween) together with 1 nM KLK14. Finally, 0.025 mM GPR-
AMC was added, and its cleavage was monitored for 12 hours.
Initial velocities were determined by linear regression and plotted
with their SD.
Distribution was calculated using the Shapiro–Wilk test, resulting in
normal distribution of data sets in all statistical analyses. Student’s
t-test was used to calculate significance levels, taking Po0.05 as
significant a priori.
Fluorescent microscopy
Paraffin sections (5mm) of tissue samples were deparaffinized and
rehydrated before heat-induced antigen retrieval was performed in
0.01 M citrate buffer (pH 6.0). Slides were blocked with 10% bovine
serum albumin. Staining was performed at 4 1C overnight using an
affinity-purified polyclonal goat antibody against SPINK6, 2mg ml 1,
and subsequently a rabbit anti-TGM1 or anti-TGM3 antibody (Zedira,
1:100). After washing, slides were incubated with a mixture of
secondary antibodies (chicken anti-goat Alexa Fluor 488, 1:5,000
and a donkey anti-rabbit Alexa Fluor 546, 1:5,000; Invitrogen) for
1 hour at room temperature. Sections were counterstained with the
DNA-selective bisbenzimide dye (Hoechst 33258). To exclude
artificial autofluorescence secondary to the preparation of the
sections, control sections were stained without primary antibodies
and no unspecific labeling was observed following incubation with
secondary antibodies (data not shown). Fluorescent pictures were
taken using a Keyence BZ9000 microscope and the automated
Z-stack algorithm (Keyence, Neu-Isenburg, Germany).
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